- Report
- March 2024
- 184 Pages
Global
From €3262EUR$3,374USD£2,804GBP
€3624EUR$3,749USD£3,115GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- November 2023
- 139 Pages
Global
From €3079EUR$3,185USD£2,646GBP
€4399EUR$4,550USD£3,781GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,202GBP
- Book
- July 2009
- 1116 Pages
Felbamate is a drug used to treat epilepsy and other seizure disorders. It is classified as an anticonvulsant and is used to reduce the frequency and severity of seizures. It is also used to treat Lennox-Gastaut syndrome, a rare form of epilepsy. Felbamate is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to reduce the frequency and severity of seizures. It is usually prescribed in combination with other anticonvulsants, such as phenytoin or valproic acid.
Felbamate is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 1993. It is not widely used, as it is more expensive than other anticonvulsants and has been linked to rare but serious side effects. Despite this, it is still prescribed to some patients who have not responded to other treatments.
The felbamate market is relatively small, with only a few companies producing the drug. These include Mylan Pharmaceuticals, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more